These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12403072)

  • 21. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
    Fujita D; Saito Y; Nakanishi T; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
    Guo S; Zhang X; Gan L; Zhu C; Gan Y
    J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
    Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
    Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
    Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
    Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
    Chu XY; Kato Y; Sugiyama Y
    Cancer Res; 1997 May; 57(10):1934-8. PubMed ID: 9157988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion.
    Atsumi R; Suzuki W; Hakusui H
    Xenobiotica; 1991 Sep; 21(9):1159-69. PubMed ID: 1788984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
    Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
    Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
    Hu Z; Yang X; Ho PC; Chan E; Chan SY; Xu C; Li X; Zhu YZ; Duan W; Chen X; Huang M; Yang H; Zhou S
    Pharm Res; 2005 Jun; 22(6):902-14. PubMed ID: 15948034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data.
    Ueda K; Kato Y; Komatsu K; Sugiyama Y
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1036-43. PubMed ID: 11356926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
    Atsumi R; Okazaki O; Hakusui H
    Biol Pharm Bull; 1995 Aug; 18(8):1114-9. PubMed ID: 8535406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
    Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
    Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of probenecid on the biliary excretion of belotecan.
    Namkoong EM; Kim IW; Kim DD; Chung SJ; Shim CK
    Arch Pharm Res; 2007 Nov; 30(11):1482-8. PubMed ID: 18087819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacokinetic study of cancer chemotherapy].
    Itoh T
    Yakugaku Zasshi; 2006 Sep; 126(9):723-35. PubMed ID: 16946586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver.
    Farabos C; Haaz MC; Gires P; Robert J
    J Pharm Sci; 2001 Jun; 90(6):722-31. PubMed ID: 11357175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
    Lin LC; Wang MN; Tsai TH
    Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
    Lokiec F; Canal P; Gay C; Chatelut E; Armand JP; Roché H; Bugat R; Gonçalvès E; Mathieu-Boué A
    Cancer Chemother Pharmacol; 1995; 36(1):79-82. PubMed ID: 7720181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.